Exchange: NASDAQ·Updated 04:20 PM EST

SGMT News

News
all
press releases
HC Wainwright Has Bearish Estimate for SGMT FY2026 Earnings
Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Research analysts at HC Wainwright lowered their FY2026 earnings estimates for Sagimet Biosciences in a report released on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($1...
MarketBeat
HC Wainwright Has Bearish Estimate for SGMT FY2026 Earnings
Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Research analysts at HC Wainwright lowered their FY2026 earnings estimates for Sagimet Biosciences in a report released on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($1...
MarketBeat
More News
Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at HC Wainwright cut their FY2030 EPS estimates for Sagimet Biosciences in a research report issued on Friday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of...
MarketBeat
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.read more...
Benzinga
Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.
Stocktwits
Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion...
Yahoo! Finance: News
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks

Advertisement|Remove ads.